See more : FS KKR Capital Corp. (FSK) Income Statement Analysis – Financial Results
Complete financial analysis of RenovaCare, Inc. (RCAR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RenovaCare, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Arizona Metals Corp. (AMC.TO) Income Statement Analysis – Financial Results
- REACT Group PLC (REAT.L) Income Statement Analysis – Financial Results
- Evolis SA (ALTVO.PA) Income Statement Analysis – Financial Results
- Jiin Ming Industry Co., Ltd. (3230.TWO) Income Statement Analysis – Financial Results
- Sonalis Consumer Products Limi (SONALIS.BO) Income Statement Analysis – Financial Results
RenovaCare, Inc. (RCAR)
About RenovaCare, Inc.
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name to RenovaCare, Inc. in January 2014. RenovaCare, Inc. is based in Scottsdale, Arizona.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.49K | 32.79K | 39.85K | 51.13K | 13.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 919.42K | 463.29K | 153.71K | 0.00 | 66.43K |
| Cost of Revenue | 0.00 | 10.97K | 22.02K | 264.00 | 317.00 | 317.00 | 53.00 | 0.00 | 0.00 | 0.00 | 32.39K | 249.18K | 24.99K | 42.98K | 9.08K | 9.83K | 56.55K | 25.52K | 0.00 | 0.00 | 226.35K | 258.61K | -138.82K | 0.00 | 0.00 |
| Gross Profit | 0.00 | -10.97K | -22.02K | -264.00 | -317.00 | -317.00 | -53.00 | 0.00 | 0.00 | 0.00 | -12.89K | -216.39K | 14.86K | 8.15K | 4.69K | -9.83K | -56.55K | -25.52K | 0.00 | 0.00 | 693.06K | 204.68K | 292.53K | 0.00 | 66.43K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -66.14% | -660.00% | 37.29% | 15.94% | 34.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 75.38% | 44.18% | 190.31% | 0.00% | 100.00% |
| Research & Development | 0.00 | 3.20M | 4.13M | 745.95K | 368.95K | 574.09K | 309.50K | 281.22K | 975.67K | 0.00 | 0.00 | 36.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 2.20M | 5.54M | 2.94M | 1.64M | 2.12M | 1.59M | 1.04M | 1.16M | 628.55K | 248.60K | 536.09K | 0.00 | 312.16K | 0.00 | 7.95K | 47.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.29K | 34.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 2.20M | 5.54M | 2.94M | 1.64M | 2.12M | 1.59M | 1.04M | 1.16M | 628.55K | 248.60K | 536.09K | 215.46K | 312.16K | 190.69K | 27.24K | 81.84K | 56.54K | 133.67K | 579.71K | 845.67K | 558.77K | 967.59K | 747.99K | 355.02K |
| Other Expenses | 0.00 | 931.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.33K | 3.26K | 107.16K | 0.00 | 93.44K | 375.00 | 1.06K | 14.17K | 42.96K | 125.32K | 125.32K | 0.00 | 0.00 | 0.00 | 14.34K |
| Operating Expenses | 0.00 | 5.41M | 9.68M | 3.69M | 2.01M | 2.70M | 1.90M | 1.32M | 2.13M | 628.55K | 261.93K | 576.21K | 322.62K | 312.16K | 284.14K | 27.61K | 82.90K | 70.71K | 176.63K | 705.03K | 970.99K | 558.77K | 967.59K | 747.99K | 369.36K |
| Cost & Expenses | 0.00 | 5.41M | 9.68M | 3.69M | 2.01M | 2.70M | 1.90M | 1.32M | 2.13M | 628.55K | 261.93K | 825.39K | 347.61K | 355.15K | 293.22K | 27.61K | 82.90K | 70.71K | 176.63K | 705.03K | 1.20M | 817.38K | 828.77K | 747.99K | 369.36K |
| Interest Income | 0.00 | 6.42K | 128.76K | 332.24K | 22.45K | 3.14K | 1.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.30K | 2.93K | 1.86K | 2.75K | 1.58K | 5.82K | 16.04K | 36.13K | 86.60K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 135.27K | 996.65K | 180.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 375.00 | 1.06K | 0.00 | 0.00 | 614.00 | 518.00 | 0.00 | 0.00 | 38.33K | 71.06K |
| Depreciation & Amortization | 228.49K | 10.97K | 22.02K | 264.00 | 317.00 | 317.00 | 53.00 | 1.31K | 2.13K | 2.22 | 1.53K | 3.26K | 4.04M | -1.24M | 93.44K | 0.00 | -36.04K | 14.17K | 42.96K | 125.32K | 125.32K | 170.89K | 183.09K | 0.00 | 0.00 |
| EBITDA | 0.00 | -5.40M | -9.53M | -3.36M | -2.01M | -2.70M | -1.90M | -1.32M | -2.13M | -628.55K | -239.38K | -786.07K | 3.65M | -596.92K | -186.00K | -27.61K | -104.23K | -53.80K | -133.67K | -579.71K | -152.61K | -183.21K | -491.98K | -747.99K | -302.93K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,227.96% | -18,420.46% | 9,163.04% | -3,671.87% | -1,350.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -16.60% | -39.54% | -320.06% | 0.00% | -456.05% |
| Operating Income | 0.00 | -5.41M | -9.68M | -3.69M | -2.01M | -2.70M | -1.90M | -1.32M | -2.13M | -628.55K | -243.96K | -792.60K | -387.01K | -639.91K | -279.45K | -27.61K | -82.90K | -70.71K | -176.63K | -705.03K | -277.93K | -354.09K | -858.15K | -747.99K | -302.93K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,251.46% | -2,417.42% | -971.25% | -1,251.43% | -2,029.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -30.23% | -76.43% | -558.29% | 0.00% | -456.05% |
| Total Other Income/Expenses | 0.00 | 937.69K | 128.76K | 332.24K | -112.82K | -993.52K | -179.67K | 0.00 | 0.00 | 0.00 | 0.00 | 5.25M | -3.88M | 1.91M | 14.30K | 2.55K | 59.23K | 2.75K | 1.58K | 5.21K | 15.52K | 0.00 | 0.00 | 0.00 | 302.93K |
| Income Before Tax | 0.00 | -4.47M | -9.55M | -3.36M | -2.12M | -3.69M | -2.08M | -1.32M | -2.13M | -628.55K | -243.96K | 4.46M | -4.35M | 1.27M | -372.89K | 0.00 | -46.87K | -67.97K | -175.05K | -699.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,251.46% | 13,595.58% | -10,906.67% | 2,482.79% | -2,708.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.42K | -128.76K | 160.64K | 22.45K | 3.14K | 15.22K | -1.31K | -2.13K | 404.24K | 1.53K | -5.25M | -79.25K | -335.89K | -107.74K | 24.68K | -1.86K | 0.00 | 0.00 | 0.00 | -15.52K | -36.13K | 96.48K | 709.66K | 231.88K |
| Net Income | 0.00 | -4.47M | -9.42M | -3.36M | -2.12M | -3.69M | -2.08M | -1.32M | -2.13M | -1.03M | -243.96K | 4.46M | -4.27M | 1.27M | -265.15K | -24.68K | -45.00K | -67.97K | -175.05K | -699.82K | -262.40K | -317.97K | -771.55K | -709.66K | -231.88K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,251.46% | 13,595.58% | -10,707.79% | 2,482.79% | -1,925.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28.54% | -68.63% | -501.95% | 0.00% | -349.08% |
| EPS | 0.00 | -0.05 | -0.11 | -0.04 | -0.03 | -0.05 | -0.03 | -0.02 | -0.03 | -0.02 | 0.00 | 0.07 | -0.07 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.03 | -0.07 | -0.03 | -0.01 |
| EPS Diluted | 0.00 | -0.05 | -0.11 | -0.04 | -0.03 | -0.05 | -0.03 | -0.02 | -0.03 | -0.02 | 0.00 | 0.07 | -0.07 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.03 | -0.07 | -0.03 | -0.01 |
| Weighted Avg Shares Out | 0.00 | 87.35M | 87.35M | 87.24M | 77.75M | 74.39M | 69.77M | 67.23M | 66.58M | 63.40M | 63.08M | 63.08M | 63.08M | 63.08M | 59.37M | 96.52M | 96.63M | 96.63M | 96.63M | 96.63M | 15.98M | 11.80M | 11.80M | 23.24M | 23.05M |
| Weighted Avg Shares Out (Dil) | 0.00 | 87.35M | 87.35M | 87.24M | 77.75M | 74.39M | 69.77M | 67.23M | 66.58M | 63.40M | 63.08M | 63.08M | 63.08M | 63.08M | 59.37M | 96.52M | 96.63M | 96.63M | 96.63M | 96.63M | 15.98M | 11.80M | 11.80M | 23.24M | 23.05M |
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against RenovaCare, Inc. (RCAR)
LOS ANGELES--(BUSINESS WIRE)---- $RCAR #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against RenovaCare, Inc. (RCAR)
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RenovaCare, Inc. ("RenovaCare" or "the Company") (OTC Pink: RCAR) for violations of §§10(b)...
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RenovaCare, Inc. ("RenovaCare" or "the Company") (OTC Pink: RCAR) for violations of §§10(b)...
TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RenovaCare, Inc. ("RenovaCare" or "the Company") (OTC Pink: RCAR) for violations of §§10(b)...
TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RenovaCare, Inc. ("RenovaCare" or "the Company") (OTC Pink: RCAR) for violations of §§10(b)...
RenovaCare Shareholder Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In RenovaCare To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 8, 2021) - Faruqi & Faruqi, LLP, a leading national securities...
RenovaCare Shareholder Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In RenovaCare To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 8, 2021) - Faruqi & Faruqi, LLP, a leading national securities...
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against RenovaCare, Inc. (RCAR)
LOS ANGELES, Sept. 8, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming September 14, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or...
RCAR Loss Alert: Rosen, Trusted National Trial Counsel, Encourages RenovaCare, Inc. Investors with Losses to Secure Counsel Before Important September 14 Deadline in Securities Class Action - RCAR
New York, New York--(Newsfile Corp. - September 7, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of RenovaCare, Inc. (OTC Pink: RCAR) between August 14, 2017 and May 28, 2021, inclusive (the...
RCAR Loss Alert: Rosen, Trusted National Trial Counsel, Encourages RenovaCare, Inc. Investors with Losses to Secure Counsel Before Important September 14 Deadline in Securities Class Action - RCAR
New York, New York--(Newsfile Corp. - September 7, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of RenovaCare, Inc. (OTC Pink: RCAR) between August 14, 2017 and May 28, 2021, inclusive (the...
Source: https://incomestatements.info
Category: Stock Reports